Alopecia AreataEarly Phase 1NCT06527729
A Novel Formulation of Sildenafil-loaded Nanocarriers for Treatment of Alopecia Areata
A Early Phase 1 study testing sildenafil-loaded liposomes and minoxidil gel in people with Alopecia Areata, run by Assiut University at 1 site in Egypt.
Trial summary
Alopecia areata (AA) is a common cause of nonscarring alopecia that occurs in a patchy, confluent, or diffuse pattern. Many theories were implicated in pathogenesis of AA, such as an autoimmune lymphocytic attack of the hair, genetic basis, and environmental factors. Read more about this study
- Who is it for?
- Ages 10 to 40 years
- Conditions the study is for
- Alopecia Areata
- What is being tested?
- sildenafil-loaded liposomes and minoxidil gel
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 28 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Jul 2021to 1 Oct 2022
- Phase
- Early Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 10 to 40 years
- All sexes
- No healthy volunteers
- Child, Adult
Who may be able to join
- Patients with a clinical and dermoscopic diagnosis of patchy alopecia areata of the scalp.
Who cannot join
- Alopecia totalis/universalis.
- Ophiasis.
- Those with systemic and/or other dermatological diseases.
- Those receiving treatment for a lopecia areata in the previous 3 months.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Sildenafil-loaded Lipid-based Nanocarrier as a Potential Therapy for Alopecia Areata: A Randomized Clinical Study
Alopecia areata (AA) is a common cause of nonscarring alopecia that occurs in a patchy, confluent, or diffuse pattern. Many theories were implicated in pathogenesis of AA, such as an autoimmune lymphocytic attack of the hair, genetic basis, and environmental factors. Clinically, AA presents as a well-circumscribed patch of sudden hair loss. It affects any hair bearing area with the scalp being the most commonly affected site .
Dermoscopy is a noninvasive technique for the clinical diagnosis of many skin diseases. Dermoscopy is now considered as a valuable tool in diagnosis of variable skin lesions. Scalp dermoscopy (Trichoscopy) does not only facilitate diagnosis of hair disorders but also give clues about disease stage and progression.
Read more
The most common trichoscopic features of AA are yellow dots, micro-exclamation mark hairs, tapered hairs, black dots, broken hairs, and regrowing upright or regrowing coiled hairs. Trichoscopic characteristics have a clinical significance in AA for diagnosis and prognosis.
The treatment of alopecia areata involves promotion of hair growth (for instance with topical minoxidil application), immunosuppression (intralesional or systemic steroid therapy, phototherapy) or immunomodulation (anthralin, dinitrochlorobenzene, diphenylcyclopropenone, squaric acid dibutylester).Unfortunately, there is currently no cure for this chronic disease, and despite the presence of a wide variety of therapeutic options, none is universally proven to induce and/or sustain remission. Development of new drugs and formulations is urgently needed
Sildenafil, a phosphodiesterase 5 (PDE5) inhibitor, is known to increase the intracellular level of cyclic guanosine monophosphate (cGMP), which causes vasodilation. Sildenafil was first approved in 1998 for erectile dysfunction, but since then additional uses for the drug have been found. A previous study demonstrated the significant therapeutic potential of sildenafil on hair growth and proposed its potential use in treatment of alopecia. It has been shown that it enhances proliferation of human dermal papilla cells (hDPCs) and up-regulates the mRNA expression of vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF), which are responsible for hair growth. Additionally, sildenafil up-regulates the levels of phosphorylated ERK and accelerates anagen induction by stimulating perifollicular vessel formation after topical application in mice.
Read the detailed description
The aim of the present work was to optimize sildenafil-loaded liposomes which could enhance percutaneous absorption and follicular penetration of sildenafil achieving improved therapeutic efficiency with minimal unnecessary side effects due to oral administration.
In addition, the study aimed to assess the efficacy of topical sildenafil-loaded liposomes formulation compared with topical minoxidil therapy for the treatment of patchy AA of the scalp through examination of its clinical effects along with dermoscopic findings.
Materials Lipoid S75 (phosphatidylcholine (70 %) with fat-free soybean phospholipids) was kindly donated by lipoid company (Germany). Sildenafil citrate was purchased from Fagron Iberica SAU. Acetonitrile HPLC reagent was purchased from Fisher Chemical. Ultrapure water was. Cholesterol was purchased from Fluka chemical co. (India). Ethanol (absolute) was purchased from El-Nasr Pharmaceuticals, (Egypt). All reagents and chemicals were purchased from (Sigma Aldrich).
Methodology Preparation of SIL-LIP using spraying technique SIL-LIP were formulated using spraying method. Pre-calculated amounts of Lipoid s75, cholesterol and sildenafil were dissolved in 2 ml of absolute ethanol and the prepared solution was transferred to a spraying apparatus [20]. In a closed system, the alcoholic solution of sildenafil and lipids was sprayed (100 ul were sprayed every 10 seconds) onto the surface of 2 ml distilled water containing sucrose (9% w/v) with stirring at 1250 rpm at 25º C. Stirring was maintained until complete evaporation of ethanol. To guarantee complete annealing of the formed liposomes, SIL-LIP were kept at 4°C overnight [21]. SIL-LIP were imaged using (JEM-1400,-Jeol,-Tokyo,-Japan) maintained at 80-kV. SIL-LIP was-left for ten minutes at 25°C before examination on carbon-coated-copper-grid.
Particle size measurement To gain more insight into size and size distribution, laser light diffraction was employed. the Prepared SIL-LIP were diluted with deionized water and was analyzed with Mastersizer 3000E Malvern Instruments, UK at 25°C. The result was the average of three repeated values.
Entrapment efficiency (E.E) of prepared liposomes
The EE% was determined by centrifugation of liposomal suspension at 1.000 rpm for 45 min at 4 °C to isolate the unentrapped sildenafil in the supernatant for indirect determination of EE% . The amount of sildenafil in the supernatant was determined by UV spectrophotometer (Spectronic Genesys®, Winspec Software, Spectronic, USA) at 228 nm . EE (%) was calculated as follows:
EE (%) = [(Qi -Qs)/Qt] × 100 where Qi is the initial amount of the sildenafil added during preparation and Qs is the sildenafil amount determined in the supernatant after centrifugation Clinical study A prospective randomized controlled study was conducted in the department of Dermatology, Assiut University Hospital including patients with patchy AA of scalp, aged between 10 and 40 years. Patients having alopecia totalis/universalis, or ophiasis, those with systemic and/or other dermatological diseases and those receiving treatment for AA in the previous 3 months were excluded.
This study was conducted in compliance with the guidelines of the Declaration of Helsinki and the study protocol was approved by the Research Ethics Committee of Faculty of Medicine, Assiut University (IRB no. 17300458). Informed consent was obtained from all patients before enrolments.
At the initial visit, full history taking and thorough clinical examination was done for all patients. The diagnosis was established based on both clinical and dermoscopic examination.
Treatment Protocol
Patients were randomly assigned to use either topical 5% minoxidil gel or topical 1% sildenafil-loaded liposomes twice daily for a period of 8 weeks.
Assessment criteria
Clinical evaluation was performed by the comparison of serial photographs of the lesions to the baseline ones. Severity of Alopecia Tool (SALT) score was calculated, at baseline, 4 weeks and 8 weeks and the average percentage of hair re-growth was determined using the SALT scoring system for hair re-growth and graded as A0: no change or further hair loss, A1: 1-24% hair re-growth, A2: 25-49% hair re-growth, A3: 50-74% hair regrowth, A4: 75-99% hair re-growth, and A5: 100% hair re-growth .
Dermoscopic examination was carried out before treatment and at 4 and 8 weeks, using the handheld dermoscope (DermLite DL4, 3Gen, Inc., San Juan Capistrano, CA 92675). Baseline and post-therapy digital photographs of dermoscopic fields were taken using an iPhone 6S smartphone camera. Dermoscopic features of AA were evaluated including yellow dots, black dots, broken hair, exclamation-mark hairs, short vellus hair and regrowing hair . Two dermoscopic fields were examined; one from the center and the other at 3 o'clock position of the alopecia patch. Trichoscopic parameters in each field were evaluated and quantified.
Data analysis was done using the SPSS software version 24 (SPSS Inc., Chicago, IL, USA). The Chi-square test and Mann-Whitney test were used for comparison of qualitative data and quantitative data, respectively. P < 0.05 was considered statistically significant.
- Conditions
- Alopecia Areata
- Being tested
- sildenafil-loaded liposomes, minoxidil gel
- Medical subject headings
- Alopecia Areata
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
sildenafil-loaded liposomesDrug
Topical 1% sildenafil-loaded liposomes was applied twice daily for a period of 8 weeks over patchy alopecia areata of the scalp.
minoxidil gelDrug
Topical 5% minoxidil gel was applied twice daily for a period of 8 weeks.
| Study group | Role | What they receive |
|---|---|---|
| Group 1 | Active comparator | Topical 5% minoxidil gel was applied twice daily for a period of 8 weeks. Receives: Drug: minoxidil gel |
| Group 2 | Experimental | Topical 1% sildenafil-loaded liposomes was applied twice daily for a period of 8 weeks. Receives: Drug: sildenafil-loaded liposomes |
What is being measured
The primary outcome is the main question the study is designed to answer.
The efficacy of topical sildenafil-loaded liposomes formulation compared with topical minoxidil therapy for the treatment of patchy alopecia areata
the comparison of serial photographs of the lesions to the baseline ones. Severity of Alopecia Tool (SALT) score was calculated, at baseline, 4 weeks and 8 weeks and the average percentage of hair re-growth was determined using the SALT scoring system for hair re-growth and graded as A0: no change or further hair loss, A1: 1-24% hair re-growth, A2: 25-49% hair re-growth, A3: 50-74% hair regrowth, A4: 75-99% hair re-growth, and A5: 100% hair re-growth
Measured: 8 weeks
Dermoscopic asessment
Dermoscopic examination was carried out before treatment and at 4 and 8 weeks, using the handheld dermoscope (DermLite DL4, 3Gen, Inc., San Juan Capistrano, CA 92675). Baseline and post-therapy digital photographs of dermoscopic fields were taken using an iPhone 6S smartphone camera. Dermoscopic features of AA were evaluated including yellow dots, black dots, broken hair, exclamation-mark hairs, short vellus hair and regrowing hair. Two dermoscopic fields were examined; one from the center and the other at 3 o'clock position of the alopecia patch. Trichoscopic parameters in each field were evaluated and quantified.
Measured: 8 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Jul 2024
- Study start1 Jul 2021
- Primary completion1 Jun 2022
- Study completion1 Oct 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Alopecia AreataStudies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Early Phase 1
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Patients were randomly assigned to use either topical 5% minoxidil gel or topical 1% sildenafil-loaded liposomes twice daily for a period of 8 weeks.
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 28 participants (actual)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Eman Fathy Ahmed, Assiut University
- Investigators
- Eman Fathy, MD, Principal investigator, Assiut university, Faculty of Medicine, Egypt
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06527729
- Sponsor's protocol ID
- Sildenafil-loaded nanocarriers
- Status last verified
- Jul 2024
- First submitted
- 14 Jul 2024
- Last updated
- 30 Jul 2024
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes
Publications
Owis AI, El-Hawary MS, El Amir D, Refaat H, Alaaeldin E, Aly OM, Elrehany MA, Kamel MS. Flavonoids of Salvadora persica L. (meswak) and its liposomal formulation as a potential inhibitor of SARS-CoV-2. RSC Adv. 2021 Apr 12;11(22):13537-13544. doi: 10.1039/d1ra00142f. eCollection 2021 Apr 7.
PubMed 35423847
Study at a glance
From the registry record, last updated by the sponsor on 30 Jul 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Sildenafil-loaded Lipid-based Nanocarrier as a Potential Therapy for Alopecia Areata: A Randomized Clinical Study
- ClinicalTrials.gov ID
- NCT06527729
- Acronym / sponsor ID
- Sildenafil-loaded nanocarriers
- Conditions
- Alopecia Areata
- Phase
- Early Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 28 participants (actual)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Study start
- 1 Jul 2021 (actual)
- Primary completion
- 1 Jun 2022 (actual)
- Study completion
- 1 Oct 2022 (actual)
- First posted
- 30 Jul 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Alopecia areata (AA) is a common cause of nonscarring alopecia that occurs in a patchy, confluent, or diffuse pattern. Many theories were implicated in pathogenesis of AA, such as an autoimmune lymphocytic attack of the hair, genetic basis, and environmental factors. Clinically, AA presents as a well-circumscribed patch of sudden hair loss. It affects any hair bearing area with the scalp being the most commonly affected site .
Dermoscopy is a noninvasive technique for the clinical diagnosis of many skin diseases. Dermoscopy is now considered as a valuable tool in diagnosis of variable skin lesions. Scalp dermoscopy (Trichoscopy) does not only facilitate diagnosis of hair disorders but also give clues about disease stage and progression.
The most common trichoscopic features of AA are yellow dots, micro-exclamation mark hairs, tapered hairs, black dots, broken hairs, and regrowing upright or regrowing coiled hairs. Trichoscopic characteristics have a clinical significance in AA for diagnosis and prognosis.
The treatment of alopecia areata involves promotion of hair growth (for instance with topical minoxidil application), immunosuppression (intralesional or systemic steroid therapy, phototherapy) or immunomodulation (anthralin, dinitrochlorobenzene, diphenylcyclopropenone, squaric acid dibutylester).Unfortunately, there is currently no cure for this chronic disease, and despite the presence of a wide variety of therapeutic options, none is universally proven to induce and/or sustain remission. Development of new drugs and formulations is urgently needed
Sildenafil, a phosphodiesterase 5 (PDE5) inhibitor, is known to increase the intracellular level of cyclic guanosine monophosphate (cGMP), which causes vasodilation. Sildenafil was first approved in 1998 for erectile dysfunction, but since then additional uses for the drug have been found. A previous study demonstrated the significant therapeutic potential of sildenafil on hair growth and proposed its potential use in treatment of alopecia. It has been shown that it enhances proliferation of human dermal papilla cells (hDPCs) and up-regulates the mRNA expression of vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF), which are responsible for hair growth. Additionally, sildenafil up-regulates the levels of phosphorylated ERK and accelerates anagen induction by stimulating perifollicular vessel formation after topical application in mice.
Detailed description
The aim of the present work was to optimize sildenafil-loaded liposomes which could enhance percutaneous absorption and follicular penetration of sildenafil achieving improved therapeutic efficiency with minimal unnecessary side effects due to oral administration.
In addition, the study aimed to assess the efficacy of topical sildenafil-loaded liposomes formulation compared with topical minoxidil therapy for the treatment of patchy AA of the scalp through examination of its clinical effects along with dermoscopic findings.
Materials Lipoid S75 (phosphatidylcholine (70 %) with fat-free soybean phospholipids) was kindly donated by lipoid company (Germany). Sildenafil citrate was purchased from Fagron Iberica SAU. Acetonitrile HPLC reagent was purchased from Fisher Chemical. Ultrapure water was. Cholesterol was purchased from Fluka chemical co. (India). Ethanol (absolute) was purchased from El-Nasr Pharmaceuticals, (Egypt). All reagents and chemicals were purchased from (Sigma Aldrich).
Methodology Preparation of SIL-LIP using spraying technique SIL-LIP were formulated using spraying method. Pre-calculated amounts of Lipoid s75, cholesterol and sildenafil were dissolved in 2 ml of absolute ethanol and the prepared solution was transferred to a spraying apparatus [20]. In a closed system, the alcoholic solution of sildenafil and lipids was sprayed (100 ul were sprayed every 10 seconds) onto the surface of 2 ml distilled water containing sucrose (9% w/v) with stirring at 1250 rpm at 25º C. Stirring was maintained until complete evaporation of ethanol. To guarantee complete annealing of the formed liposomes, SIL-LIP were kept at 4°C overnight [21]. SIL-LIP were imaged using (JEM-1400,-Jeol,-Tokyo,-Japan) maintained at 80-kV. SIL-LIP was-left for ten minutes at 25°C before examination on carbon-coated-copper-grid.
Particle size measurement To gain more insight into size and size distribution, laser light diffraction was employed. the Prepared SIL-LIP were diluted with deionized water and was analyzed with Mastersizer 3000E Malvern Instruments, UK at 25°C. The result was the average of three repeated values.
Entrapment efficiency (E.E) of prepared liposomes
The EE% was determined by centrifugation of liposomal suspension at 1.000 rpm for 45 min at 4 °C to isolate the unentrapped sildenafil in the supernatant for indirect determination of EE% . The amount of sildenafil in the supernatant was determined by UV spectrophotometer (Spectronic Genesys®, Winspec Software, Spectronic, USA) at 228 nm . EE (%) was calculated as follows:
EE (%) = [(Qi -Qs)/Qt] × 100 where Qi is the initial amount of the sildenafil added during preparation and Qs is the sildenafil amount determined in the supernatant after centrifugation Clinical study A prospective randomized controlled study was conducted in the department of Dermatology, Assiut University Hospital including patients with patchy AA of scalp, aged between 10 and 40 years. Patients having alopecia totalis/universalis, or ophiasis, those with systemic and/or other dermatological diseases and those receiving treatment for AA in the previous 3 months were excluded.
This study was conducted in compliance with the guidelines of the Declaration of Helsinki and the study protocol was approved by the Research Ethics Committee of Faculty of Medicine, Assiut University (IRB no. 17300458). Informed consent was obtained from all patients before enrolments.
At the initial visit, full history taking and thorough clinical examination was done for all patients. The diagnosis was established based on both clinical and dermoscopic examination.
Treatment Protocol
Patients were randomly assigned to use either topical 5% minoxidil gel or topical 1% sildenafil-loaded liposomes twice daily for a period of 8 weeks.
Assessment criteria
Clinical evaluation was performed by the comparison of serial photographs of the lesions to the baseline ones. Severity of Alopecia Tool (SALT) score was calculated, at baseline, 4 weeks and 8 weeks and the average percentage of hair re-growth was determined using the SALT scoring system for hair re-growth and graded as A0: no change or further hair loss, A1: 1-24% hair re-growth, A2: 25-49% hair re-growth, A3: 50-74% hair regrowth, A4: 75-99% hair re-growth, and A5: 100% hair re-growth .
Dermoscopic examination was carried out before treatment and at 4 and 8 weeks, using the handheld dermoscope (DermLite DL4, 3Gen, Inc., San Juan Capistrano, CA 92675). Baseline and post-therapy digital photographs of dermoscopic fields were taken using an iPhone 6S smartphone camera. Dermoscopic features of AA were evaluated including yellow dots, black dots, broken hair, exclamation-mark hairs, short vellus hair and regrowing hair . Two dermoscopic fields were examined; one from the center and the other at 3 o'clock position of the alopecia patch. Trichoscopic parameters in each field were evaluated and quantified.
Data analysis was done using the SPSS software version 24 (SPSS Inc., Chicago, IL, USA). The Chi-square test and Mann-Whitney test were used for comparison of qualitative data and quantitative data, respectively. P < 0.05 was considered statistically significant.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
- Model description
- Patients were randomly assigned to use either topical 5% minoxidil gel or topical 1% sildenafil-loaded liposomes twice daily for a period of 8 weeks.
| Arm | Type | Receives |
|---|---|---|
| Group 1 | Active comparator | Drug: minoxidil gelTopical 5% minoxidil gel was applied twice daily for a period of 8 weeks. |
| Group 2 | Experimental | Drug: sildenafil-loaded liposomesTopical 1% sildenafil-loaded liposomes was applied twice daily for a period of 8 weeks. |
Who may qualify
- Ages
- 10 to 40 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
Key inclusion criteria (1 listed)
- Patients with a clinical and dermoscopic diagnosis of patchy alopecia areata of the scalp.
Key exclusion criteria (4 listed)
- Alopecia totalis/universalis.
- Ophiasis.
- Those with systemic and/or other dermatological diseases.
- Those receiving treatment for a lopecia areata in the previous 3 months.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| sildenafil-loaded liposomesTopical 1% sildenafil-loaded liposomes was applied twice daily for a period of 8 weeks over patchy alopecia areata of the scalp. | Drug | Group 2 |
| minoxidil gelTopical 5% minoxidil gel was applied twice daily for a period of 8 weeks. | Drug | Group 1 |
Primary outcome
The efficacy of topical sildenafil-loaded liposomes formulation compared with topical minoxidil therapy for the treatment of patchy alopecia areata
Time frame: 8 weeks
the comparison of serial photographs of the lesions to the baseline ones. Severity of Alopecia Tool (SALT) score was calculated, at baseline, 4 weeks and 8 weeks and the average percentage of hair re-growth was determined using the SALT scoring system for hair re-growth and graded as A0: no change or further hair loss, A1: 1-24% hair re-growth, A2: 25-49% hair re-growth, A3: 50-74% hair regrowth, A4: 75-99% hair re-growth, and A5: 100% hair re-growth
Dermoscopic asessment
Time frame: 8 weeks
Dermoscopic examination was carried out before treatment and at 4 and 8 weeks, using the handheld dermoscope (DermLite DL4, 3Gen, Inc., San Juan Capistrano, CA 92675). Baseline and post-therapy digital photographs of dermoscopic fields were taken using an iPhone 6S smartphone camera. Dermoscopic features of AA were evaluated including yellow dots, black dots, broken hair, exclamation-mark hairs, short vellus hair and regrowing hair. Two dermoscopic fields were examined; one from the center and the other at 3 o'clock position of the alopecia patch. Trichoscopic parameters in each field were evaluated and quantified.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Jul 2024.
- Background: PubMed 35423847Owis AI, El-Hawary MS, El Amir D, Refaat H, Alaaeldin E, Aly OM, Elrehany MA, Kamel MS. Flavonoids of Salvadora persica L. (meswak) and its liposomal formulation as a potential inhibitor of SARS-CoV-2. RSC Adv. 2021 Apr 12;11(22):13537-13544. doi: 10.1039/d1ra00142f. eCollection 2021 Apr 7.
- Individual participant dataSharing planned: Yes
Related trials for Alopecia Areata
Active, not recruitingPhase 3
A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata
Severe Alopecia Areata
RecruitingPhase 2
Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata
Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (Apeced), Alopecia Areata
Active, not recruitingObservational study
Litfulo Capsules Special Investigation
Alopecia Areata
Active, not recruitingObservational study
Real-World Effectiveness of Ritlecitinib in Alopecia Areata Patients in the US: A Retrospective Analysis Using EHR and Claims Data
Alopecia Areata
Active, not recruitingObservational study
Characterization And Clinical Outcomes of AA Patients Treated With Ritlecitinib
Alopecia Areata
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Eman Fathy, MD principal investigator
Assiut university, Faculty of Medicine, Egypt
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Early Phase 1 study testing sildenafil-loaded liposomes and minoxidil gel in people with Alopecia Areata, run by Assiut University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 30 Jul 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Early Phase 1 (sometimes called Phase 0) studies give a very small amount of a treatment to a few people, mainly to see how the body handles it.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The efficacy of topical sildenafil-loaded liposomes formulation compared with topical minoxidil therapy for the treatment of patchy alopecia areata (time frame: 8 weeks). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06527729, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Jul 2024.